Selecta Biosciences to Present at the SVB Leerink 10th Annual Global Healthcare Conference
Selecta Biosciences, Inc. (NASDAQ: SELB) announced that CEO Carsten Brunn, Ph.D., will deliver a corporate update and participate in investor meetings at the SVB Leerink 10th Annual Global Healthcare Conference, scheduled for February 24-26, 2021. Brunn's presentation will take place on February 26 at 10 a.m. ET and will be accessible via the conference portal. Selecta is focused on developing tolerogenic therapies through its ImmTOR™ platform, with clinical trials for its AAV gene therapy anticipated to start early in 2021.
- None.
- None.
WATERTOWN, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will provide a corporate update and participate in one-on-one investor meetings at the SVB Leerink 10th Annual Global Healthcare Conference taking place February 24 – 26, 2021.
The presentation on Friday, February 26 at 10 a.m. ET will be available through the SVB Leerink Conference portal and an archived webcast will also be accessible in the Investors & Media section of the company’s website at www.selectabio.com.
About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. The company’s first program aimed at addressing immunogenicity to AAV gene therapies is expected to enter clinical trials in early 2021 in partnership with AskBio for the treatment of methylmalonic acidemia (MMA), a rare metabolic disorder. A wholly-owned program focused on addressing IgA nephropathy driven by ImmTOR and a therapeutic enzyme is also in development among additional product candidates. Selecta recently licensed its Phase 3 clinical product candidate, SEL-212, in chronic refractory gout to Sobi. For more information, please visit www.selectabio.com.
For Investors:
Bruce Mackle
LifeSci Advisors, LLC
+1-929-469-3859
bmackle@lifesciadvisors.com
For Media:
Meredith Sosulski, Ph.D.
LifeSci Communications, LLC
+1-929-469-3851
msosulski@lifescicomms.com
FAQ
What is the date of Selecta Biosciences' presentation at the SVB Leerink Conference?
Who is presenting for Selecta Biosciences at the SVB Leerink Conference?
What is the main focus of Selecta Biosciences as outlined in the PR?
When is Selecta's AAV gene therapy expected to enter clinical trials?
What is the stock symbol for Selecta Biosciences?
